Stephane Bancel - Oct 19, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Oct 19, 2022
Transactions value $
-$10,995,415
Form type
4
Date filed
10/21/2022, 04:16 PM
Previous filing
Oct 14, 2022
Next filing
Oct 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $39.6K +40K +0.74% $0.99* 5.45M Oct 19, 2022 Direct F1
transaction MRNA Common Stock Sale -$1.77M -14.3K -0.26% $123.74 5.44M Oct 19, 2022 Direct F1, F2
transaction MRNA Common Stock Sale -$1.21M -9.74K -0.18% $124.60 5.43M Oct 19, 2022 Direct F1, F3
transaction MRNA Common Stock Sale -$544K -4.33K -0.08% $125.54 5.42M Oct 19, 2022 Direct F1, F4
transaction MRNA Common Stock Sale -$455K -3.59K -0.07% $126.83 5.42M Oct 19, 2022 Direct F1, F5
transaction MRNA Common Stock Sale -$593K -4.65K -0.09% $127.64 5.42M Oct 19, 2022 Direct F1, F6
transaction MRNA Common Stock Sale -$440K -3.42K -0.06% $128.73 5.41M Oct 19, 2022 Direct F1, F7
transaction MRNA Common Stock Options Exercise $39.6K +40K +0.74% $0.99* 5.45M Oct 20, 2022 Direct F1
transaction MRNA Common Stock Sale -$1.24M -10.4K -0.19% $118.98 5.44M Oct 20, 2022 Direct F1, F8
transaction MRNA Common Stock Sale -$530K -4.43K -0.08% $119.67 5.44M Oct 20, 2022 Direct F1, F9
transaction MRNA Common Stock Sale -$1.91M -15.8K -0.29% $121.08 5.42M Oct 20, 2022 Direct F1, F10
transaction MRNA Common Stock Sale -$220K -1.8K -0.03% $122.26 5.42M Oct 20, 2022 Direct F1, F11
transaction MRNA Common Stock Sale -$763K -6.2K -0.11% $123.04 5.41M Oct 20, 2022 Direct F1, F12
transaction MRNA Common Stock Sale -$173K -1.4K -0.03% $123.77 5.41M Oct 20, 2022 Direct F1, F13
transaction MRNA Common Stock Sale -$1.23M -10K -0.15% $122.94 6.66M Oct 20, 2022 See Footnote F14, F15
holding MRNA Common Stock 9.05M Oct 19, 2022 See Footnote F16

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -40K -1.38% $0.00 2.87M Oct 19, 2022 Common Stock 40K $0.99 Direct F1, F17
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -40K -1.4% $0.00 2.83M Oct 20, 2022 Common Stock 40K $0.99 Direct F1, F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.05 to $124.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.10 to $125.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.12 to $126.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.23 to $127.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.25 to $128.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.27 to $129.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.40 to $119.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.41 to $120.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.43 to $121.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F11 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.58 to $122.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F12 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.59 to $123.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F13 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.60 to $124.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F14 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
F15 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F16 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F17 This option is fully vested and exercisable.